New drug targets Fuel-Hungry lung cancer cells in phase 2 trial

NCT ID NCT07249372

Recruiting now Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called DRP-104 in people with advanced non-small cell lung cancer that has specific gene changes (NFE2L2 or KEAP1). The drug works by blocking glutamine, a nutrient cancer cells need to grow. The trial aims to see if the drug can shrink tumors or slow the disease after standard treatments have stopped working. About 37 adults will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Columbia University
RECRUITING

New York, New York, 10032, United States
NYU Langone Health
RECRUITING

New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.